LGWM
BMRN icon

Litman Gregory Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Litman Gregory Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16
Closed -$1K – 213
2019
Q3 		$1K Sell
16
-16
-50% -$1.23K ﹤0.01% 196
2019
Q2 		$3K Buy
+32
New +$2.74K ﹤0.01% 194

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Litman Gregory Wealth Management's BMRN Position: Q4 2019 in Review

Litman Gregory Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 16 shares — an estimated $1K sold.

Litman Gregory Wealth Management first reported a position in BMRN in Q2 2019 and held it in 2 quarters. The position peaked at $3K in Q2 2019. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • Litman Gregory Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Litman Gregory Wealth Management sold 16 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $1K.
  • Litman Gregory Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Litman Gregory Wealth Management's BioMarin Pharmaceuticals position peaked at $3K in Q2 2019.
  • 467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Litman Gregory Wealth Management's 13F filing for Q4 2019, filed 30 Jan 2020.